Meeting
2019 Gastrointestinal Cancers Symposium
A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).
Authors
Hiroki Yukami
Department of Cancer Chemotherapy Center, Osaka Medical Collage Hospital, Osaka, Japan
Hiroki Yukami , Masahiro Goto , Takayuki Kii , Tetsuji Terazawa , Toshifumi Yamaguchi , Fukutaro Shimamoto , Hitoshi Nishitani , Hisato Kawakami , Toshio Shimokawa , Yoshihiro Matsubara , Daisuke Sakai , Yukinori Kurokawa , Taroh Satoh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006864
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 144)
DOI
10.1200/JCO.2019.37.4_suppl.144
Abstract #
144
Poster Bd #
L16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong
Poster
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
First Author: Changhoon Yoo